Last week, we wrote about the opportunity that the global recession is presenting to India and their clinical trials.
While the cost of clinical trials vary on the basis of complexity and disease segment, a simple trial in India can cost 15-20% of the US price, while a more sophisticated trial—involving imaging systems—may be 50-60% of the US price. Studies suggest that R&D expenditure is increasing by 15% per year, making global biopharmaceutical companies look for cheaper options. India scores high due to faster enrollments, speed of completion, large and diverse patient pool as well as increasing private healthcare network.
The Economic Times takes a deeper look into this belief. Read more here.
Search This Blog
Blog Archive
-
▼
2008
(97)
-
▼
November
(15)
- Clinical Trials Market Expected to Grow in India D...
- Parexel Completes Chinese Bridging Study
- CROs Under Fire
- CRO BioReliance Enters Tech-Development
- India's clinical trials not affected by the recession
- MarketWatch: Quintiles, SAS Announce Development o...
- Biotrial, Full-Service CRO and European Leader in ...
- Economic Crisis Presents an Opportunity for the In...
- Mayo Clinic Pulls Out of Clinical Services
- MarketWatch: EyeGate Pharma Enrolls First Dry Eye ...
- Outsourced Clinical Trials Going Through a Rough P...
- Kendle sees revenue increase
- Nurse dismissed for error in clinical trials
- Nigeria Opens Clinical Trial Center
- India, China, Latin America and CEE as Clinical Tr...
-
▼
November
(15)
India's clinical trials industry continues to explode, lack of experienced clinical research employees in the region is slowing down progress. The potential is huge, multinationals are willing and Indian companies are eager.
ReplyDelete------------------
jnny
influencer